Chemotherapy vs tamoxifen in platinum-resistant ovarian cancer: a phase III, randomised, multicentre trial (Ovaresist)

BACKGROUND: Chemotherapy in platinum-resistant ovarian cancer (PROC) aims for palliation and prolonging of progression-free survival (PFS). This study compares Health-related Quality of Life (HRQoL) and efficacy between single-agent chemotherapy and tamoxifen in PROC. METHODS: Patients with PROC wer...

Descripción completa

Detalles Bibliográficos
Autores principales: Lindemann, Kristina, Gibbs, Emma, Åvall-Lundqvist, Elisabeth, dePont Christensen, Rene, Woie, Kathrine, Kalling, Marten, Auranen, Annika, Grenman, Seija, Hoegberg, Thomas, Rosenberg, Per, Skeie-Jensen, Tone, Hjerpe, Elisabet, Dørum, Anne, Gebski, Val, Kristensen, Gunnar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2017
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5318972/
https://www.ncbi.nlm.nih.gov/pubmed/28118323
http://dx.doi.org/10.1038/bjc.2016.435

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5318972/
https://www.ncbi.nlm.nih.gov/pubmed/28118323
http://dx.doi.org/10.1038/bjc.2016.435

Ejemplares similares